Recent Updates
Recently added Catalysts

ACELYRIN, INC.

SLRNFDA catalysts, PDUFA dates & pipeline intelligence
$2.27
▲ +0.03 · +1.34%

Last traded May 20, 2025. This price is not current.

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full SLRN financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $1.8552W HIGH $7.25
Volume
4.08 M
Value Traded
9.30 M
Short % Float
4.25%
Days to Cover
3.9
-9.92%Week
+3.65%1 Month
+7.08%3 Month
-46.71%6 Month
-90.13%5 Year
-90.13%All Time

Cash Data

Unlock SLRN cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
229.16 M
EPS (TTM)
-2.69
P/E Ratio
-
Ent. Value
-175.46 M
Total Shares
100.95 M
Float Shares
77.87 M
Insiders
16.75%
Institutions
42.50%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 3 topline data readout
Lonigutamab
thyroid eye disease
Phase 3BiologicsOphthalmologic System
Unlock every SLRN catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

SLRN Catalyst Timeline

Dated clinical, regulatory and corporate events for ACELYRIN, INC.

Unlock the full SLRN catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How SLRN actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2024-09-25Izokibep Phase 3 data readout Phase 3
Unlock all SLRN historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Showing 4 of 4 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
ABY-035 Monoclonal antibodyCompletedNCT04713072Psoriatic ArthritisPhase 2 COMPLETED 129Jan 27, 2022
Izokibep Small moleculeCompletedNCT05355805Hidradenitis SuppurativaPhase 2 COMPLETED 205Feb 21, 2024
Izokibep Small moleculeCompletedNCT04706741UveitisPhase 2 COMPLETED 7Nov 14, 2022
lonigutamab Monoclonal antibodyCompletedNCT05683496Thyroid Eye DiseasePhase 1/2 COMPLETED 31May 26, 2025
Unlock the SLRN pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every SLRN program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
lonigutamab Thyroid Eye DiseasePhase 22025-01-06robust efficacy in TED patients comparable to the IV administered standard of care; no reported cases of hearing impairment, hyperglycemia or menstrual disorders to dateRead MoreACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye DiseaseRead More
Scroll for more · summaries link to the source press release
Unlock every SLRN trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock SLRN insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Kim MinaDirector, Officer (Chief Executive Officer)Sell -17,986 671,753 held$2.74 03/17/2025
Unlock the full SLRN insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in SLRN

Fund % of Portfolio Current MV Shares Owned Activity
TANG CAPITAL MANAGEMENT LLC 1.3 % 24.25 M 9.82 M
Unlock every fund holding SLRN
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in SLRN
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see SLRN ownership
Insider and institutional ownership, quarter by quarter.

SLRN Short Interest

Shares sold short, counted twice a month.

4.25%
Short % of Float
of tradable shares sold short
4.2M
Shares Sold Short
+18.9% vs prior count
3.9 Moderate
Days to Cover
trading days of normal volume to buy every short share back
1.1M
Avg Daily Volume
the average used for days to cover
Unlock SLRN short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock SLRN option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live SLRN option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock SLRN options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How SLRN ranks across every disease it competes in

Competitive Position is a premium feature
See how SLRN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

SLRN News

About ACELYRIN, INC.

BIOPHARMAWATCH ELITE PLUS
Trade the next SLRN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime